For example, RORγ agonists, which can activate BMAL1 transcription [48], attenuate the expression of PD-1 receptors, and LYC-55716, a RORy inhibitor, is currently under a Phase 1 trial used in combination with pembrolizumab for NSCLC (NCT03396497). The gene discussed is RORC; the disease is non-small cell lung carcinoma.